Research progress of PROTACs in the treatment of prostate cancer
10.3760/cma.j.cn112330-20221117-00616
- VernacularTitle:PROTAC药物在前列腺癌治疗中的研究进展
- Author:
Sihan ZHANG
1
;
Qidong XIA
;
Shaogang WANG
Author Information
1. 华中科技大学同济医学院附属同济医院泌尿外科，武汉 430030
- Keywords:
Prostate neoplasms;
Carcinoma;
Proteolysis targeting chimera;
Therapeutic target;
Clinical trials
- From:
Chinese Journal of Urology
2023;44(11):873-876
- CountryChina
- Language:Chinese
-
Abstract:
The major challenges in drug therapy for prostate cancer are the ineffectiveness and resistance to androgen deprivation therapy, the low response to immunotherapy and the poor efficacy of small molecule targeted drugs. As a brand-new drug design concept, proteolysis targeting chimera (PROTAC) reveals its strength in the field of cancer treatment by connecting the target protein to the ubiquitin-proteasome system and triggering the degradation of the target protein. In recent years, basic medical research on targeting androgen receptors, cell proliferation, and transcriptional regulation proteins for the treatment of prostate cancer has achieved significant progress. Meanwhile, clinical trials related to PROTAC for the treatment of prostate cancer are gradually being carried out. In an era of big data and precision medicine, PROTAC is a breakthrough in the field of prostate cancer drug therapy. This article summarizes the fundamental principles of PROTACs and the basic and clinical research advances in the field of prostate cancer treatment.
